OUR PIPELINE
About Us
At Adiso, we create medicines to treat inflammatory diseases, to improve the lives of patients and their families. We believe that current therapeutic approaches are often inadequate to halt disease progression or run the risk of burdening the patient with significant safety concerns.
To tackle these challenges, we are advancing an innovative, multi-modal pipeline of small molecules and single strain live biotherapeutic products all with novel mechanisms of action. Our approach is scientifically and clinically cutting edge in that it is both targeted and locally acting at the site of inflammation.
ADS051 is a first-in-class modulator of neutrophil activity which is nearing completion of a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing ADS032, a novel small molecule that acts as a dual inflammasome inhibitor (NLRP3 & NLRP1), it has entered IND enabling studies for the treatment of respiratory and dermal inflammation. ADS024 (SS-LBP) has just completed a Phase 1b study for the prevention of recurrent CDI and is Phase 2 ready for our moderate ulcerative colitis (UC) trial.
Team & Founders
Leadership Team
Discovery Team
Paul Ross, PhD
University College Cork, Ireland/APC Microbiome Institute
Colin Hill, PhD
University College Cork, Ireland/APC Microbiome Institute
Beth McCormick, PhD
The University of Massachusetts Chan Medical School
Small Molecule Modulator of Neutrophil Trafficking and Activation
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS051
Ulcerative Colitis
ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FRP1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and restricted to the gut with limited systemic exposure.
Single Strain Live Biotherapeutic Product (SS-LBP) Platform
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS024
Prevention of CDI Recurrence
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.
ADS024
Ulcerative Colitis
ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.
First-In-Class Small Molecule Inhibitor of the NLRP1 and 3 Inflammasomes
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS032
Respiratory Inflammation
ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide
range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases.
News
Contact Us
530 Virginia Road, Suite 300,
Concord, MA 017422 Broad Street, Dana Building, 2nd Floor,
Hopewell, NJ 08525